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pro-inﬂammatory and catabolic cytokines; MCP-1, TNF-α, IL-1β and genes
encoding proteins linked to atrogenesis including; SOCS3 and atrogin-1.
Results: OA patients had signiﬁcantly greater levels of the pro-
inﬂammatory cytokines MCP-1 mRNA (Fig 1A) and TNF-α mRNA (Fig.
1B), compared to both MA and Y individuals. OA also tended to have
higher levels of IL-1β mRNA and SOCS3 mRNA, compared to MA but these
differences did not reach statistical signiﬁcance (p>0.05). No signiﬁcant
differences were observed between asymptomatic MA and asymptomatic Y
with the exception of MCP-1 (Fig. 1A).
Figure 1. Differences in MCP-1 (A), TNF-α (B), IL-1β (C), SOCS3 (D) and Atrogin-1 (panel
E) between people with severe knee osteoarthritis (OA), aged and BMI matched asymp-
tomatic individuals (MA) and young (Y) asymptomatic individuals. * indicates p<0.05 be-
tween MA and OA groups. #indicates p<0.05 between Y and OA. ˆindicates p<0.05 be-
tween Y and MA.
Conclusions: Cytokines were implicated in OA, yet also feature in catabolic
disease states in which muscle loss is a feature. The current study
demonstrates that OA resulted in a signiﬁcant increase gene expression of
numerous muscle inﬂammatory markers, compared to asymptomatic aged
and BMI-matched peers. Ageing had little effect on muscle inﬂammation
(MA versus Y).
Given the importance of inﬂammatory-mediated mechanisms in muscle
atrophy, the impact of the increased inﬂammatory markers may be exerting
on muscular mass and function in OA required further analysis.
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Purpose: Synovial inﬂammation may play a role in the progression of
joint destruction in osteoarthritis (OA). Activation of synoviocytes by pro-
inﬂammatory stimuli results in the release of biochemical mediators such
as matrix metalloproteinases (MMPs), chemokines, cytokines etc. We have
previously shown that heme oxygenase-1 (HO-1) induction down-regulates
MMPs and HMGB1 in OA synoviocytes. In this study we aim to evaluate the
effects of the HO-1 pathway on cell migration and chemokine production
as well as the signaling pathways involved.
Methods: Synovial tissue samples were obtained from 15 osteoarthritic pa-
tients undergoing total knee joint replacement. Synoviocytes were obtained
by digestion with collagenase and cultured until third passage. Cells were
treated with the HO-1 inducer cobalt protoporphyrin IX (CoPP, 10 μM) or
the CO-releasing molecule CORM-2 (100 μM) in the presence or absence of
IL-1β (10 ng/ml). HO-1 gene silencing was achieved by speciﬁc HO-1 siRNA.
Gene expression was analyzed by quantitative PCR and protein expression
by Western Blot and ELISA. Migration assay was performed using transwell
chambers.
Results: Treatment of synoviocytes with CoPP signiﬁcantly decreased both
mRNA and protein expression of CCL2 and CCL20 chemokines, with a weak
effect on IL-8 levels. Conversely, CORM-2 treatment signiﬁcantly decreased
protein levels of IL-8, CCL2 and CCL20. HO-1 down-regulation by siRNA
counteracted the effects of HO-1 induction. Interestingly, the reduction on
chemokine levels by either CoPP or CORM-2 was accompanied by a signif-
icant reduction in the migration index elicited by IL-1β. We observed that
CoPP treatment signiﬁcantly decreased ERK 1/2 and JNK phosphorylation,
whereas CORM-2 markedly diminished the phosphorylation of ERK1/2, JNK
and p38.
Conclusions: Taken together, our data show the inhibitory effect of the
HO-1 pathway, either by direct induction of HO-1 or by the release of CO, a
metabolite of the reaction catalized by HO-1, on chemokine production and
cell migration. These effects may be dependent on the inhibition of MAPK
phosphorylation. These data support our previous results and suggest that
targeting the HO-1 pathway may represent a potential strategy to control
OA progression.
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Purpose: Osteoarthritis is characterized by degeneration of articular car-
tilage and intra-articular inﬂammation in response to cytokines such
as IL-1beta or TNFalpha. These cytokines increase the synthesis of
prostaglandin E2 (PGE2) by stimulating cyclooxygenase (COX)-2, microso-
mal PGE synthase-1 (mPGES-1), and secreted phospholipase A2 (sPLA2).
NSAIDs provide symptomatic relief, but none has conclusive eﬃcacy as
a disease modifying anti-osteoarthritic drug with non negligeable side
effects. Inhibiting the PGE2 production in cartilage without affecting the
COX1-COX2 balance could be of interest in order to replace traditional
NSAIDs whose side effects are not in accordance with a long-term use.
Group IIA secreted/synovial PLA2 (GIIAPLA2) is an enzyme involved in
the synthesis of eicosanoids such as PGE2. PGE2 is the main eicosanoid
contributing to extra-cellular matrix degradation in cartilage diseases.
Methods: We designed, by molecular modeling, 7 novel analogs of
3-{4-[5(indol-1-yl)pentoxy]benzyl}-4H-1,2,4-oxadiazol-5-one (termed C1),
an inhibitor of GIIAPLA2. Molecular dynamics studies were performed on
a series of complexes between “C derivatives” (C1 to C8) and GIIAPLA2.
The C1 to C8 molecules were obtained by chemical synthesis and their
GIIAPLA2 inhibitory activities were tested using in vitro PLA2 enzymatic
tests. We then tested the most promising compound (C8) in rabbit articular
chondrocytes treated by IL-1beta: we evaluated the cytotoxicity of C8 by
using a MTT-based test, we quantiﬁed its capacity to inhibit IL-1beta-
stimulated PGE2 and NO secretion, and we tested its effect on the COX1,
COX2 and iNOS protein levels.
Results: Modeling predicted that some derivatives would display greater
GIIAPLA2 aﬃnities than C1. These predictions were conﬁrmed by in vitro
PLA2 enzymatic tests. Compound C8, endowed with the most favorable
energy balance, was shown experimentally to be the strongest GIIAPLA2
inhibitor. Moreover, C8 displayed an anti-inﬂammatory activity on rabbit
articular chondrocytes, as shown by its capacity to inhibit IL-1beta-
stimulated PGE2 secretion by these cells. Moreover, depending on the
culture conditions, C8 had no effect or a slight effect on IL-1beta-stimulated
NO secretion. In addition, C8 did not modify the COX1, COX2, iNOS protein
levels.
Conclusion: In conclusion, C8 appears as a potential candidate for new
anti-inﬂammatory drug in joints, implying a better tolerance.
